Cipla achieved record revenue exceeding ₹28,000 Cr, with India business crossing ₹12,500 Cr and cash reserves at ₹11,000 Cr.

Global markets, including North America ($780M) and Africa ($483M), showed robust growth driven by new complex products like generic Ventolin.

R&D spending (7% revenue) fuels future pipeline amidst US generics pricing pressure.